Cleared Traditional

K913421 - NASAL OXYGEN CANNULA, 81585, 81587 & 81589 (FDA 510(k) Clearance)

Class I Anesthesiology device.

K913421 · Specialty Packaging Producs, Inc. · Anesthesiology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Oct 1991
Decision
79d
Days
Class 1
Risk

K913421 is an FDA 510(k) clearance for the NASAL OXYGEN CANNULA, 81585, 81587 & 81589. Classified as Cannula, Nasal, Oxygen (product code CAT), Class I - General Controls.

Submitted by Specialty Packaging Producs, Inc. (El Paso, US). The FDA issued a Cleared decision on October 18, 1991 after a review of 79 days - a notably fast clearance cycle.

This device falls under the Anesthesiology FDA review panel, regulated under 21 CFR 868.5340 - the FDA anesthesiology and respiratory device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Specialty Packaging Producs, Inc. devices

Submission Details

510(k) Number K913421 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received July 31, 1991
Decision Date October 18, 1991
Days to Decision 79 days
Submission Type Traditional
Review Panel Anesthesiology (AN)
Summary Statement
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
60d faster than avg
Panel avg: 139d · This submission: 79d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code CAT Cannula, Nasal, Oxygen
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 868.5340
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.